<DOC>
	<DOCNO>NCT00509795</DOCNO>
	<brief_summary>This study phase 3 , double-masked , randomize , study efficacy safety VEGF Trap-Eye patient neovascular age-related macular degeneration . Approximately 1200 patient randomize US Canada .</brief_summary>
	<brief_title>Vascular Endothelial Growth Factor VEGF Trap-Eye : Investigation Efficacy Safety Wet Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Signed Informed Consent . 2 . Men woman â‰¥ 50 year age . 3 . Active primary recurrent subfoveal CNV lesion secondary AMD , include juxtafoveal lesion affect fovea evidence FA study eye . 4 . Early Treatment Diabetic Retinopathy Study ( ETDRS ) Best Corrected Visual Acuity ( BCVA ) : letter score 73 25 ( 20/40 20/320 ) study eye 4 meter . 5 . Willing , commit , able return ALL clinic visit complete studyrelated procedure . 6 . Able read , ( , unable read due visual impairment , read verbatim person administer informed consent family member . See Appendix J.4 ) understand willing sign inform consent form . Key 1 . Any prior ocular ( study eye ) systemic treatment surgery neovascular AMD except dietary supplement vitamin . 2 . Any prior concomitant therapy another investigational agent treat neovascular AMD study eye , except dietary supplement vitamin . 3 . Any prior treatment antiVEGF agent study eye . 4 . Total lesion size &gt; 12 disc area ( 30.5 mm^2 , include blood , scar neovascularization ) assess FA study eye . 5 . Subretinal hemorrhage either 50 % total lesion area , blood fovea 1 disc area size study eye . ( If blood fovea , fovea must surround 270 degree visible CNV . ) 6 . Scar fibrosis , make &gt; 50 % total lesion study eye . 7 . Scar , fibrosis , atrophy involve center fovea . 8 . Presence retinal pigment epithelial tear rip involve macula study eye . 9 . History vitreous hemorrhage within 4 week prior Visit 1 study eye . 10 . Presence cause CNV study eye . 11 . History clinical evidence diabetic retinopathy , diabetic macular edema vascular disease affect retina , AMD , either eye . 12 . Prior vitrectomy study eye . 13 . History retinal detachment treatment surgery retinal detachment study eye . 14 . Any history macular hole stage 2 study eye . 15 . Any intraocular periocular surgery within 3 month Day 1 study eye , except lid surgery , may take place within 1 month day 1 , long unlikely interfere injection .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>